MgIClinicalStudies.com
Title
Irofulven: Prostate Cancer
Description
Phase II clinical trial for hormone-refractory disease by the MGI Pharma company.
Contact
- MGI PHARMA, Inc.
-

- Bloomington MN
- US 55437
-

- 5775
Irofulven: Prostate Cancer
Phase II clinical trial for hormone-refractory disease by the MGI Pharma company.

